Literature DB >> 8142311

Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression.

M Borrás1, L Hardy, F Lempereur, A H el Khissiin, N Legros, R Gol-Winkler, G Leclercq.   

Abstract

Incubation of MCF-7 cells with estradiol (E2) down-regulates estrogen receptor (ER) resulting in a progressive reduction of the capacity of cells to concentrate selectively [3H]E2. Scatchard plot analysis failed to detect any transformation of residual receptors into peptides of lower binding affinity. [3H]Estrone gave an identical ER disappearance pattern with an ER half-life comprised between 2 and 3 h. A similar value was established by incubating the cells with [3H]tamoxifenaziridine ([3H]TAZ) for 1 h before the addition of excessive unlabeled E2 which induced ER-down regulation and impeded any further labeling of the residual receptors. Submission of the [3H]TAZ labeled cell extracts to SDS-PAGE revealed no progressive emergence of low molecular weight cleavage products of the receptor (< 67 kDa). Two inhibitors of protein kinases, H-7 at 40 microM and H-89 at 20 microM, failed to block the E2-induced ER down-regulation. On the contrary, the protein phosphatases 1 and 2A inhibitor, okadaic acid, was effective with concentrations higher than 0.1 microM indicating that a dephosphorylation mechanism was involved in this phenomenon. Cycloheximide (CHX) also significantly reduced the receptor decrease at concentrations higher than 1 microM. G-C specific intercalating agents [actinomycin D (AMD) and chromomycin A3 at 1 microM] also prevented ER disappearance; ethidium bromide (EB) and quinacrine were ineffective. AMD and CHX operated immediately after their addition to the medium indicating an inhibitory action on the synthesis of an RNA and/or a peptide with high turnover rate involved in ER decline. Moreover, AMD produced its suppressive effects under conditions impeding any labeling of newly synthetized receptors (i.e. [3H]TAZ with an excess of unlabeled E2) rejecting the possibility of an increasing ER production which may partially hamper its disappearance. Finally, E2-induced ER mRNA down-regulation was similarly abolished by AMD while EB and CHX were devoid of effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142311     DOI: 10.1016/0960-0760(94)90072-8

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  22 in total

1.  Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.

Authors:  Christopher C Valley; Raphaël Métivier; Natalia M Solodin; Amy M Fowler; Mara T Mashek; Lindsay Hill; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

2.  Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.

Authors:  Olga Ch Kousidou; Aikaterini Berdiaki; Dimitris Kletsas; Alexandros Zafiropoulos; Achilleas D Theocharis; George N Tzanakakis; Nikos K Karamanos
Journal:  Mol Oncol       Date:  2008-06-18       Impact factor: 6.603

3.  Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.

Authors:  M H Herynk; M T Lewis; T A Hopp; D Medina; A Corona-Rodriguez; Y Cui; A R Beyer; S A W Fuqua
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

4.  Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.

Authors:  P Rajbhandari; K A Schalper; N M Solodin; S J Ellison-Zelski; K Ping Lu; D L Rimm; E T Alarid
Journal:  Oncogene       Date:  2013-04-01       Impact factor: 9.867

5.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

Review 6.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

7.  Divergent Regulation of ER and Kiss Genes by 17β-Estradiol in Hypothalamic ARC Versus AVPV Models.

Authors:  Alice K Treen; Vicky Luo; Jennifer A Chalmers; Prasad S Dalvi; Dean Tran; Wenqing Ye; Ginah L Kim; Zoey Friedman; Denise D Belsham
Journal:  Mol Endocrinol       Date:  2016-01-04

8.  Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.

Authors:  Angela M Davis; Jiude Mao; Bushra Naz; Jessica A Kohl; Cheryl S Rosenfeld
Journal:  J Mol Endocrinol       Date:  2008-07-16       Impact factor: 5.098

9.  Developmental estrogen exposures and disruptions to maternal behavior and brain: Effects of ethinyl estradiol, a common positive control.

Authors:  Mary C Catanese; Laura N Vandenberg
Journal:  Horm Behav       Date:  2017-11-08       Impact factor: 3.587

10.  Single nucleotide polymorphism 6q25.1 rs2046210 and increased risk of breast cancer.

Authors:  Jing Pei; Fang Li; Benzhong Wang
Journal:  Tumour Biol       Date:  2013-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.